- Home
- ENLT vs CPRX Comparison
ENLT vs CPRX Comparison
Compare ENLT & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- CPRX
- Stock Information
- Founded
- ENLT 2008
- CPRX 2002
- Country
- ENLT Israel
- CPRX United States
- Employees
- ENLT N/A
- CPRX N/A
- Industry
- ENLT
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ENLT
- CPRX Health Care
- Exchange
- ENLT Nasdaq
- CPRX Nasdaq
- Market Cap
- ENLT 2.9B
- CPRX 2.6B
- IPO Year
- ENLT 2023
- CPRX 2006
- Fundamental
- Price
- ENLT $31.31
- CPRX $20.84
- Analyst Decision
- ENLT Hold
- CPRX Strong Buy
- Analyst Count
- ENLT 4
- CPRX 5
- Target Price
- ENLT $26.00
- CPRX $33.20
- AVG Volume (30 Days)
- ENLT 26.0K
- CPRX 1.7M
- Earning Date
- ENLT 11-12-2025
- CPRX 11-05-2025
- Dividend Yield
- ENLT N/A
- CPRX N/A
- EPS Growth
- ENLT N/A
- CPRX 183.96
- EPS
- ENLT 0.17
- CPRX 1.65
- Revenue
- ENLT $428,715,000.00
- CPRX $558,499,000.00
- Revenue This Year
- ENLT $355.90
- CPRX $16.51
- Revenue Next Year
- ENLT $42.83
- CPRX $9.58
- P/E Ratio
- ENLT $35.97
- CPRX $12.64
- Revenue Growth
- ENLT 39.54
- CPRX 28.55
- 52 Week Low
- ENLT $14.01
- CPRX $19.05
- 52 Week High
- ENLT $31.80
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- ENLT 68.45
- CPRX 58.28
- Support Level
- ENLT $29.65
- CPRX $19.05
- Resistance Level
- ENLT $31.80
- CPRX $22.02
- Average True Range (ATR)
- ENLT 0.67
- CPRX 0.60
- MACD
- ENLT 0.19
- CPRX 0.16
- Stochastic Oscillator
- ENLT 87.00
- CPRX 60.27
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).